Senores Pharmaceuticals: Beats Estimates, US Growth Engine Accelerates
Moneylife Digital Team 26 May 2026
Senores Pharmaceuticals Limited (Senores) delivered a very strong FY25-26, comfortably exceeding management guidance. Consolidated revenue grew 59% year-on-year (y-o-y) to ₹632 crore; earnings...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Get access to complete archives
Rs 5000 + GST
 
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback